Literature DB >> 24613348

Trial and error in clinical studies: lessons from ATAMS.

Fred Lühder1, Ralf Gold2.   

Abstract

Mesh：

Substances：

Year:  2014        PMID： 24613348     DOI： 10.1016/S1474-4422(14)70050-X

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  5 in total

Review 1.  Monoclonal antibodies in the treatment of multiple sclerosis: emergence of B-cell-targeted therapies.

Authors:  Ai-Lan Nguyen; Melissa Gresle; Tessa Marshall; Helmut Butzkueven; Judith Field
Journal:  Br J Pharmacol       Date:  2017-04-26       Impact factor: 8.739

Review 2.  Anti-B-Cell Therapies in Autoimmune Neurological Diseases: Rationale and Efficacy Trials.

Authors:  Harry Alexopoulos; Angie Biba; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

Review 3.  Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases.

Authors:  Panos Stathopoulos; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2022-02-18       Impact factor: 6.088

4.  Commentary: Systematic Review of Safety and Efficacy of Atacicept in Treating Immune-Mediated Disorders.

Authors:  David A Isenberg; Amy H Kao; Aida Aydemir; Joan T Merrill
Journal:  Front Immunol       Date:  2020-11-11       Impact factor: 7.561

5.  FcγRIIb Expression Is Decreased on Naive and Marginal Zone-Like B Cells From Females With Multiple Sclerosis.

Authors:  Stephanie Trend; Jonatan Leffler; Ingrid Teige; Björn Frendéus; Allan G Kermode; Martyn A French; Prue H Hart
Journal:  Front Immunol       Date:  2021-01-11       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.